Co-presented webinar will explain how the companies enhanced biospecimen collection and COVID-19 testing methods to meet pandemic demands
BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it will co-host a webinar entitled “Overcoming Supply Chain Issues During the COVID-19 Pandemic” with Mawi DNA Technologies at 11 a.m. ET on Wednesday, April 21.
“Efforts to control COVID-19 have accelerated advances in diagnostic, therapeutic, and vaccine development. But the pandemic has also strained all facets of the life sciences supply chain, generating enormous demand for personal protective equipment, swabs, and regents for COVID-19 testing, and biospecimens for developing assays and therapies and investigating vaccine immune responses,” said Cathie G. Miller, PhD, Senior Director of Product Marketing, Personalized Medicine at BioIVT. “BioIVT has risen to the challenge and supported 400+ clients with COVID-19-related specimens, across a broad range of inclusion/exclusion criteria.”
During this webinar, Dr. Miller will discuss how BioIVT has leveraged its experience and knowledge of biospecimen procurement, donor outreach, IRB-approved collection/processing protocols, and data and sample validation to support clients’ COVID-19 R&D. She will describe how the company rapidly established new collection networks, including an at-home service for quarantined COVID-19 patients, to secure vital samples and progress critical research worldwide.
“Realizing the tremendous need for efficient COVID-19 testing and recognizing that viral RNA extraction is one of the most time-consuming and lab-consumable-intensive steps, our company sought ways to eliminate it from the testing process,” said Despoina Lymperopoulou, PhD, Senior Scientist at Mawi DNA Technologies. “As a result, our iSWAB-Microbiome-EL (Extraction-Less) solution allows sensitive COVID-19 qPCR and LAMP assays to be validated without RNA extraction, significantly decreasing the labor, cost, and time required.”
During her presentation, Dr. Lymperopoulou will explain how this new technology enables swab and/or saliva-based collection, and stabilization and sample transportation at room temperature. iSWAB-Microbiome-EL optimizes molecular assay workflows by shortening turnaround time and it is also environmentally friendly.
Interested persons can register for this complimentary webinar at https://info.bioivt.com/mdt-wbr-reg.
About Mawi DNA Technologies
Mawi DNA Technologies has developed and commercialized the iSWAB technology, an innovative system for collection of biosamples. Its flagship product iSWAB-DNA has gained significant market traction due to its ability to be used for animals and all human population segments from infants to the elderly, with robust DNA yield and low bacterial DNA content. iSWAB-Microbiome has gained worldwide acceptance as a superior collection technology for COVID-19 samples. Mawi DNA has expanded its offerings to include collection technologies for intact cells and whole blood. For more information, visit http://www.mawidna.com.
BioIVT is a leading global provider of research models and value-added research services for drug discovery and development. We specialize in control and disease-state biospecimens including human and animal tissues, cell products, blood and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. And as the premier supplier of hepatic products, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly discovered compounds and their effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in elevating science. For more information, please visit www.bioivt.com or follow the company on Twitter @BioIVT.